Key Insights Significant control over IO Biotech by private equity firms implies that the general public has more ...

Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

Ultragenyx and partner Mereo BioPharma’s brittle bone disease trial will continue. Investors had wanted data good enough to ...

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: MoonLake ...

Love her or hate her, Cathie Wood is a true maverick who’s made a name finding tomorrow’s big disruptors long before anyone ...

Discover why IBB's focused approach makes it preferable to XBI. Learn about their objectives, diversification, and ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

Anbio Biotechnology (NASDAQ:NNNN)’s NASDAQ debut has garnered strong investor interest, resulting in a nearly 600% surge from ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $69.0, a high ...